Malaria in pregnancy: adverse pregnancy outcomes and the future of prevention

Frontiers in Tropical Diseases

Tropical Diseases

Justin Y. A. Doritchamou¹  Patrick E. Duffy¹  Anne D. Berhe² 

[1] Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States;Laboratory of Malaria Immunology and Vaccinology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, United States;Vagelos College of Physicians and Surgeons, Columbia University, New York, NY, United States;

关键词: malaria;    pregnancy;    vaccine;    perinatal death;    pre-term birth (PTB);    miscarriage;    stillbirth;    low birth weight (LBW);   

DOI  :  10.3389/fitd.2023.1229735

 received in 2023-05-26, accepted in 2023-07-12,  发布年份 2023

来源: Frontiers

【 摘 要 】

Malaria in pregnancy (MiP) poses a dangerous health risk to both mothers and their fetuses, causing severe outcomes such as preterm delivery, intrauterine growth restriction, miscarriage, stillbirth, and neonatal and maternal death. Plasmodium falciparum infected erythrocytes sequester in placental intervillous spaces causing placental malaria (PM), eliciting inflammatory responses associated with severe sequelae. Current MiP prevention strategies have improved pregnancy outcomes, but serious morbidity and mortality persist. Vaccines to prevent MiP and PM are under development and are expected to improve pregnancy outcomes. To prepare for safety and efficacy trials of these vaccines, the incidence of adverse pregnancy outcomes including those caused by MiP should be documented at clinical sites. This review summarizes reported key adverse pregnancy outcomes attributable to MiP, providing important baseline context to define measurable safety and efficacy endpoints for malaria vaccine trials in pregnancy.

【 授权许可】

Unknown   
Copyright © 2023 Berhe, Doritchamou and Duffy